Varex Imaging Corporation · NASDAQ:VREX
Varex Imaging — Q4 2022 Earnings Presentation
24 slides from Varex Imaging's earnings presentation, Nov 15, 2022

Slide 1: Q4 FY22 Earnings Presentation
Solutions in Sight® Q4 FY22 Earnings Presentation November 15, 2022

Slide 2: Forward Looking Statements / Non-GAAP Measures
Forward Looking Statements / Non-GAAP Measures Forward Looking Statements Certain statements in this supplement contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward looking statements incl

Slide 3: Q4 FY22 Results
Q4 FY22 Results Non-GAAP Non-GAAP Cash, Cash Equiv., Revenue Gross Margin* EPS* & Mkt. Sec.** $231M $113M 33% $0.42 ➢ Demand remained solid during the quarter ➢ Supply chain situation slowly improved ➢ Inflation continued to pressure margin ➢ Inventory growth moderated * Non-GAAP. For a reconciliati

Slide 4: Q4 FY22 Sequential Performance
Q4 FY22 Sequential Performance Revenue Gross Margin - Non-GAAP Adjusted EBITDA $231 35% 33% $36 $36 $214 +8% -200bps Flat Q3FY22 Q4FY22 Q3FY22 Q4FY22 Q3FY22 Q4FY22 EPS - Non-GAAP Cash, Cash Equiv. & Mkt. Sec. $0.42 $110 $113 $0.37 +14% +3% Q3FY22 Q4FY22 Q3FY22 Q4FY22 Note: $millions except for per s

Slide 5: Demand Environment
Demand Environment CT Mammography Radiography & Fluoroscopy Others Oncology Industrial Dental 5

Slide 6: FY2023 Initiatives
FY2023 Initiatives Continued execution on existing and new initiatives to drive growth • China / CT • Nanotubes / Micro-X Medical ~80% of • Cardiovascular tubes revenues • Azure, Lumen and Photon Counting • India Expansion • Security Industrial ~20% of • Systems in select verticals revenues • Photon

Slide 7: FY2022 Performance
FY2022 Performance Revenue Gross Margin - Non-GAAP Adjusted EBITDA $859 35% 34% $135 $140 $818 +5% -90bps +4% FY2021 FY2022 FY2021 FY2022 FY2021 FY2022 EPS - Non-GAAP Cash, Cash Equiv. & Mkt. $1.43 Sec. $1.31 $145 $27M debt redemption during Q2FY22 $113 +9% -22% FY2021 FY2022 FY2021 FY2022 Note: $mi

Slide 8: Q4 FY22 Revenue Details
Q4 FY22 Revenue Details Segment Mix Geographic Mix ($ in millions) ($ in millions) $50 $77 $80 $181 $74 Medical Industrial Americas EMEA APAC Revenue, $M Q4 22 Q3 22 Q2 22 Q1 22 Q4 21 Revenue, $M Q4 22 Q3 22 Q2 22 Q1 22 Q4 21 Americas 80 64 68 61 70 Medical 181 167 170 156 181 EMEA 74 70 70 67 74 In

Slide 9: Quarterly Results - GAAP
Quarterly Results - GAAP $ in Millions, except per share data Q4 FY22 Q3 FY22 Q4 FY21 Revenue $231 $214 $226 Gross Margin 32% 34% 33% $50 $50 $49 Operating Expenses 22% 23% 22% $25 $23 $27 Operating Income 11% 11% 12% Net Earnings $13 $8 $9 EPS, diluted $0.32 $0.20 $0.20 Avg. shares, diluted 40.9 40

Slide 10: Quarterly results – Non-GAAP
Quarterly results – Non-GAAP* $ in Millions, except per share data Q4 FY22 Q3 FY22 Q4 FY21 Revenue $231 $214 $226 Gross Margin (Non-GAAP) 33% 35% 34% $47 $47 $45 Operating Expenses (Non-GAAP) 20% 22% 20% $29 $28 $33 Operating Income (Non-GAAP) 13% 13% 14% Net Earnings (Non-GAAP) $17 $15 $19 EPS, dil

Slide 11: Select Balance Sheet Data
Select Balance Sheet Data $ in Millions Q4 FY22 Q3 FY22 Q4 FY21 Assets Cash, Cash Equiv. and Mkt. Sec. $113 $110 $145 Accounts Receivable, net $173 $157 $155 Inventories $303 $300 $225 Total Assets $1,184 $1,163 $1,148 Liabilities Accounts Payable $78 $83 $59 Long-Term Debt, net $414 $413 $435 Total

Slide 12: Select Debt and Cash Flow Data
Select Debt and Cash Flow Data $ in Millions Q4 FY22 Q3 FY22 Q4 FY21 Debt Gross Debt $450 $451 $481 (Ratings: Moody’s B2 / S&P B+) Net Debt1 $337 $341 $336 Adjusted EBITDA2 Adjusted EBITDA $36 $36 $40 Cash Performance Cash Flow from Operations $17 ($3) $51 Capital Expenditures $10 $4 $3 Cash Interes

Slide 13: Outlook Q1 FY23
Outlook Q1 FY23 Guidance Non-GAAP Revenues, $M $195 - $215 EPS Per Diluted Share $0.10 - $0.30 Assumptions Non-GAAP Gross Margin ~33% Operating Expenses, $M $46 - $47 13

Slide 14: Q&A
W VAREX MA G Solutions in Sight® VREX Nasdaq isted Pf Nasdaq Q&A

Slide 15: Non-GAAP Reconciliation
Solutions in Sight® Non – GAAP Reconciliation 15

Slide 16: Reconciliation between GAAP and Non-GAAP Financial measures
Reconciliation between GAAP and Non-GAAP Financial measures (unaudited) Three Months Ended Twelve Months Ended September 30, October 1, September 30, October 1, (In millions, except per share amounts) 2022 2021 2022 2021 GROSS PROFIT RECONCILIATION Revenues, net $ 231.4 $ 226.3 $ 859.4 $ 818.1 Gross

Slide 17: Reconciliation between GAAP and Non-GAAP Financial measures
Reconciliation between GAAP and Non-GAAP Financial measures (unaudited) Three Months Ended Twelve Months Ended September 30, October 1, September 30, October 1, (In millions, except per share amounts) 2022 2021 2022 2021 SELLING, GENERAL AND ADMINISTRATIVE EXPENSE RECONCILIATION Selling, general and

Slide 18: Reconciliation between GAAP and Non-GAAP Financial measures
Reconciliation between GAAP and Non-GAAP Financial measures (unaudited) Three Months Ended Twelve Months Ended September 30, October 1, September 30, October 1, (In millions, except per share amounts) 2022 2021 2022 2021 OPERATING INCOME RECONCILIATION Operating income $ 24.6 $ 26.5 $ 88.2 $ 74.1 Am

Slide 19: Reconciliation between GAAP and Non-GAAP Financial measures
Reconciliation between GAAP and Non-GAAP Financial measures (unaudited) Three Months Ended Twelve Months Ended September 30, October 1, September 30, October 1, (In millions, except per share amounts) 2022 2021 2022 2021 INCOME BEFORE TAXES RECONCILIATION Income before taxes $ 14.1 $ 14.8 $ 44.5 $ 2

Slide 20: Reconciliation between GAAP and Non-GAAP Financial measures
Reconciliation between GAAP and Non-GAAP Financial measures (unaudited) Three Months Ended Twelve Months Ended (In millions, except per share amounts) September 30, October 1, September 30, October 1, 2022 2021 2022 2021 DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING RECONCILIATION GAAP weighted averag

Slide 21: Effect of Convertible Note Hedge and Warrants on Non-GAAP Diluted Share count
Effect of Convertible Note Hedge and Warrants on Non-GAAP Diluted Share count Impact of Warrants and Convertible Note Hedge at Various Share Prices Shares added back for non- GAAP related to convertible Impact of Warrants on GAAP note hedge Share Price* Diluted Shares Non-GAAP Diluted Shares $20.00

Slide 22: Illustrative Impact of ASU 2020-06
Illustrative Impact of ASU 2020-06 Quarterly ASU 2020-06 Share Count Illustration GAAP NON-GAAP* Net Income before Incremental Dilutive Net Income before effect of Add-back of After-tax Shares for EPS effect of Add-back of After-tax Incremental Dilutive Convertible Notes ($M) Interest Expense Calcul

Slide 23: Discussion of Non – GAAP Financial Measures
Discussion of Non – GAAP Financial Measures This presentation includes non-GAAP financial measures derived from our Condensed Consolidated Statements of Earnings. These measures are not presented in accordance with, nor are they a substitute for U.S. generally accepted accounting principles, or GAAP

Slide 24: Solutions in Sight
Solutions in Sight®
Source: Internet Archive copy of vareximaging.com
More decks from Varex Imaging Corporation
Q2 2026 Earnings Presentation21 slides · May 7, 2026
Q1 2026 Earnings Presentation22 slides · Feb 10, 2026
Q4 2025 Earnings Presentation23 slides · Nov 18, 2025
Q3 2025 Earnings Presentation21 slides · Aug 7, 2025
Q2 2025 Earnings Presentation22 slides · May 8, 2025
Investor Presentation (March 2025)23 slides · March 2025